Archief longkankerstudies in Nederland

Op deze pagina vindt u een overzicht van de afgeronde longkankerstudies van de aangesloten centra. Maak gebruik van de zoek- en filterfunctie om eenvoudig door het aanbod van de afgeronde longkankerstudies te navigeren.

1479.0001 BI (Beamion Lung)

LUMC

Open label, fase 1 dosis escalatie (1a) en expansie studie (1b)

ARTEMIDE-01

LUMC

Open label, fase 1/ 2 dosis escalatie en expansie studie

Amaze-lung

Antoni van Leeuwenhoek

A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI

Amgen Tarlatamab - Dellphi304

LUMC

Open label, gerandomiseerde fase 3 studie

DF1001 – A phase I/II, first-in-human, multi-part, open-label, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of DF1001 in patients with locally advanced or metastatic solid tumors, and expanding in selected indications.

Radboud UMC

Non-randomized, open-label expansion study.

GDC-6036 + Pembrolizumab

Antoni van Leeuwenhoek

OPEN-LABEL

IMMUCAN

MUMC+

moleculaire profiling van solide tumoren

POTENTIA

Amsterdam UMC

A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients with PSMA+ Advanced and/or Metastatic Solid Tumours

STAR-121 (Gilead GS-US-626-6216)

UMC Groningen and Erasmus MC